Microsoft word - caldolor orthopedic study publication 8.30.10.doc

FOR IMMEDIATE DISTRIBUTION
PRE AND POST-OPERATIVE USE OF CALDOLOR (IBUPROFEN) INJECTION
SIGNIFICANTLY REDUCES PAIN AND OPIOID USE IN NEWLY PUBLISHED STUDY
¾ Study demonstrates IV ibuprofen can be safely administered at induction of anesthesia as well as throughout the post-operative period ¾ IV ibuprofen decreases morphine use by more than 30% while improving pain control NASHVILLE, Tenn., August 30, 2010 – Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
today announced the publication of new data supporting the safety and efficacy of Caldolor®
(ibuprofen) Injection in pre and post-operative orthopedic surgery patients. The study, which was
published in the August edition of the peer-reviewed journal Pain Medicine, concludes that IV
ibuprofen significantly decreased pain and morphine use when compared with placebo.
In the United States, more than 60 percent of patients with moderate or severe pain following
surgery receive morphine.1 Both the World Health Organization and the American Society of
Anesthesiologists Task Force recommend a multi-modal approach to pain management, with
nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen as baseline therapy, which can
minimize the risk of opioid-related side effects including sedation, nausea, vomiting, cognitive
impairment and respiratory depression.2, 3
“These findings are significant in that they not only confirm that Caldolor is effective in reducing
both post-operative pain and morphine use, but also demonstrate that it can be safely administered
prior to the induction of anesthesia,” said Neil Singla, M.D., Chief Executive Officer of Lotus
Clinical Research, Inc. and principal investigator of the study. “This gives physicians additional
options for controlling the onset of post-operative pain, which can help improve patient comfort and
thereby facilitate recovery.”
This multi-center, randomized, double-blind placebo-controlled trial evaluated 185 adult patients
undergoing orthopedic surgery at eight hospitals. Patients were randomized to receive either 800 mg
IV ibuprofen or placebo every six hours, and pain was measured through patient self-assessment
using a visual analog scale (VAS) and a verbal response scale (VRS) in the immediate post-
operative period through hour 28 of the study. All patients had access to intravenous morphine. The
study met its primary endpoint as patients who received IV ibuprofen reported a 26% reduction in
pain with movement (p<0.001). The study also met its secondary endpoints as pain assessed during
rest was reduced by 32% in patients receiving IV ibuprofen (p<0.001), and these patients used
nearly 31% less morphine than those who received placebo (p<0.001). There was no significant
difference between placebo and IV ibuprofen in the number of patients with bleeding adverse
events, the incidence of blood transfusions or other serious adverse events. More patients receiving
IV ibuprofen experienced vomiting and more patients receiving placebo experienced dyspepsia.

Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Safely Reduces Pain and Opioid Use in Newly Published Study The study demonstrated that both pre-operative and post-operative administration of Caldolor
diminished post-surgical pain. In previous clinical studies of IV ibuprofen, the initial dose was
administered intra-operatively. However, patients in this study received the first dose of study drug
at the induction of anesthesia through a peripheral or central venous catheter. Pain assessments were
performed at regular intervals following surgery, with the average first assessment occurring 2.8
hours post-operatively. The difference in pain scores between patients receiving Caldolor plus
morphine compared to morphine alone was significant at this first measurement and remained
significant at every point of measurement throughout the study period.
“This clinical study is so important because it provides strong safety and efficacy data supporting
use of Caldolor in surgical patients not only during recovery, but also when administered prior to
surgery,” said A.J. Kazimi, Chief Executive Officer at Cumberland Pharmaceuticals. “Caldolor is
the only IV-NSAID available in the United States that does not carry a contraindication for pre-
operative use, and we believe this data will provide physicians with a new level of comfort in using
IV ibuprofen to more effectively manage post-operative pain for their patients.”
The new data supports a previous randomized, placebo controlled trial in surgical patients, which
demonstrated that 800 mg of IV ibuprofen dosed every six hours produced a significant reduction in
pain and morphine use in surgical patients. The study, entitled “A Multicenter, Randomized,
Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen 400 and 800 mg Every 6 Hours in
the Management of Post-operative Pain,” was published in Volume 31, Number 9 of the peer-
reviewed journal Clinical Therapeutics in October 2009.
Introduced in 2009, Caldolor is the first new injectable product available in the United States in 20
years for IV pain treatment, and provides safe and effective relief from both pain and fever. The
newly published study, entitled “A Multicenter, Randomized, Double-Blind Placebo-Controlled
Trial of Intravenous-Ibuprofen (IV-Ibuprofen) for Treatment of Pain in Post-Operative Orthopedic
Adult Patients” appears in Volume 11 of Pain Medicine. The publication can be found online at
http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2010.00896.x/pdf.
SOURCE: Cumberland Pharmaceuticals Inc.
About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to
severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first
FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known
hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type
reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-
operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be
used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid
retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment,
and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment
with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.
Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Safely Reduces Pain and Opioid Use in Newly Published Study About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused
on the acquisition, development and commercialization of branded prescription products. The
Company's primary target markets include hospital acute care and gastroenterology. Cumberland
markets Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable
treatment for pain and fever available in the United States, and Kristalose®, a prescription laxative.
Cumberland is dedicated to providing innovative products which improve quality of care for
patients. For more information on Cumberland Pharmaceuticals, visit
www.cumberlandpharma.com.

About Pain Medicine
Pain Medicine is a multi-disciplinary journal dedicated to the pain clinician, teacher and researcher.
It is the Official Journal of the American Academy of Pain Medicine and of the Faculty of Pain
Medicine of the Australian and New Zealand College of Anaesthetists. The journal is devoted to the
advancement of pain management, education and research.
Important Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that reflect Cumberland’s current views with
respect to future events, based on what it believes are reasonable assumptions. No assurance can be
given that these events will occur. As with any business, all phases of operations are subject to
influences outside of the Company's control. Risk factors that could materially affect results of
operations include, among others, those factors discussed in Cumberland’s Annual Report filed on
Form 10-K as filed with the SEC on March 19, 2010. There can be no assurance that results or
developments anticipated by Cumberland will be realized or, even if realized, that they will have the
expected effects. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Cumberland undertakes no obligation to release
publicly any revisions to these statements to reflect events or circumstances after the date hereof or
to reflect the occurrence of unanticipated events.

Angela Novak Cumberland Pharmaceuticals 615-255-0068 [email protected] Media Contact: Rebecca Kirkham Lovell Communications 615-297-7766 [email protected] Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Safely Reduces Pain and Opioid Use in Newly Published Study 1 Carr DB, Miaskowski C, Dedrick SC, Williams GR, Management of perioperative pain in hospitalized patients: A national survey. J Clin Anesth 1998; 10:77-85. 2 World Health Organization. Pain relief and palliative care. In: Clinical Management of HIV and AIDS at District Level. New Delhi, India. WHO Regional Office for South-East Asia Web site. http://www.searo.who.int/linkfiles/publications_ch11.pdf. Updated April 26, 2006. Accessed July 15, 2009. 3 The American Society of Anesthesiologists Task Force. Practice guidelines for acute pain management in the perioperative setting. Anesthesiology. 2004; 100(6): 1573-1581.

Source: http://caldolor.bytesofknowledge.com/news/pr_083010/Caldolor-Orthopedic-Study-Publication-8-30-10.pdf